AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03230903 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: Patients will receive a written individualized exercise plan during their baseline visit on top of their usual disease care.
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: neuroimaging session (with simultaneously acquired eye-tracking)
Description: neuroimaging session, including two functional neuroimaging paradigms (ca. 15-20 minutes each) and a short structural image acquisition (mprage) for coregistration. Functional Magnetic Brain Imaging (fMRI) and simultaneous eye-tracking data will be collected during the paradigms: 1) an emotion processing paradigm (adapted from Passamonti et al., 2010); and 2) an emotional Go/noGo paradigm (adapted from Hare et al., 2008).
Study NCT00239356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
Study NCT00109005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2
Study NCT01462968 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activated clotting time versus blood-heparin concentration
Description: Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
Study NCT01462968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activated clotting time versus blood-heparin concentration
Description: Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
Study NCT03854812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: a loading of 50 mg/kg in 15 minutes of Magnesium sulphate, and will be followed by continuous infusion at 1 ml/kg/h of 15 mg/ml solution
Study NCT03854812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution
Study NCT03854812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80
Study NCT00033111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Study NCT00033111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill manufactured to mimic cabergoline 05mg tablet
Study NCT02280486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5 mg/d
Study NCT02280486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1mg/d, up titrated 1mg if FPG >6.1 mmol/L (110mg/dL) till 6 mg
Study NCT00456885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: exenatide
Description: 5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
Study NCT00456885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: 5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
Study NCT00456885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily injection of placebo
Study NCT00456885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice daily injection of placebo
Study NCT00392834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: given subcutaneously
Study NCT00392834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given IV
Study NCT03474497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: • A total of four interleukin-2 treatments will be delivered into the treatment lesion by intralesional injection biweekly (at least 48 hours apart) starting 24-96 hours after the completion of radiotherapy and to be completed during the second on-trial cycle of Pembrolizumab. Intralesional injections will be performed by direct visualization and/or palpation of the lesion or under ultrasound or CT guidance as indicated.
Study NCT03474497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be delivered at 200 mg in three week cycles per standard protocol.
Study NCT03474497 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered to the treatment lesion during the second cycle of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1-2 of cycle 2 and will not be repeated in future cycles.
Study NCT03148561 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
Study NCT03652558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone application with the Ozonytron XL device
Description: An ozone generator (Ozonytron; Bionix, Munchen, Germany) with an KPX probe (CA Probe; Ozonytron, Bionix, Munchen, Germany) was used for OT. Topical gaseous ozone was applied into the periodontal pocket twice a week for 2 weeks based on the manufacturer's instructions. Ozone applications were at 75% power for 30 seconds (75 µg/ml). Ozone applications were performed by an experienced investigator. Ozone applications in the control side were simulated without starting the ozone generator
Study NCT02828306 — intervention group
Intervention type: OTHER
Intervention: Patient Specific Implant
Description: Implantation of Patient Specific Implant
Study NCT03257514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha lipoic acid drug (thioctic acid acid)
Description: Alpha lipoic acid has anti-inflammatory, antioxidant effects and plays a role in wound healing process.
Study NCT03257514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo oral drug have the same shape of thiotacid tablet
Study NCT01865240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal Denervation Catheter
Study NCT03467880 — intervention group
Intervention type: OTHER
Intervention: Clinical Observation
Description: No treatment given but observation with IOS
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Questionnaire (for children) assessing traumatic experiences (Childhood trauma questionnaire (CTQ))
Description: The Childhood Trauma Questionnaire is a brief survey of six early traumatic experiences (death, divorce, violence, sexual abuse, illness or other), and assesses individual's understanding of their childhood trauma.
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Social and Health Assessment (SAHA) questionnaire (for children)
Description: Self reported survey assessing social and mental health with four aspects of parenting determined (parental involvement, parental warmth, parental control, and inconsistency of parenting).
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Massachusetts Youth Screening Instrument (MAYSI-2) (for children)
Description: The Massachusetts Youth Screening Instrument (MAYSI-2) is a screening instrument developed for detecting mental health needs in youth aged 12-17. Designed as a low-cost, easily administered tool, it screens for multiple issues and can be administered in 10-15 minutes. It is divided into seven scales composed of 52 questions that are designed to detect alcohol/drug use, angryirritable behavior, depression-anxiety, somatic complaints, suicide ideation, thought disturbance, and traumatic experience. Youths answer YES or NO concerning whether each item has been true for them within the past few months.
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Interpersonal Reactivity Index (IRI) (for children)
Description: The Interpersonal Reactivity Index is a measure of dispositional empathy that takes as its starting point the notion that empathy consists of a set of separate but related constructs. The instrument contains four seven-item subscales (seven Likert items each), each tapping a separate facet of empathy (Empathic Concern, Perspective Taking, Personal Distress, and Fantasy). The 28-item IRI contains four subscales
Study NCT00392834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: given IV
Study NCT00392834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: given intrathecally
Study NCT00392834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: given IV
Study NCT00392834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: given IV
Study NCT00392834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: given IV
Study NCT00392834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: given IV
Study NCT00392834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine
Description: given intrathecally
Study NCT00392834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: given intrathecally
Study NCT00392834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: given intrathecally
Study NCT00392834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: given IV
Study NCT00579553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Progesterone
Description: Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
Study NCT00579553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Progesterone
Description: Vaginal Progesterone: 100 mg vaginal suppository daily
Study NCT03726658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241751
Description: AGN-241751 is supplied in tablet form
Study NCT03726658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied in tablet form
Study NCT00190229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study NCT00412958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 25µg
Description: Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
Study NCT00412958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 75µg
Description: Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
Study NCT00412958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 125µg
Description: Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
Study NCT00412958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravitreal injection of placebo
Study NCT02818764 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: 5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
Study NCT02818764 — intervention group
Intervention type: PROCEDURE
Intervention: Cerebral Spinal Fluid collection
Description: Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
Study NCT02312011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-DMPKRx
Description: Drug
Study NCT02312011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00081939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Two cycles of induction on days 1,4,8,11 at 1.0mg/m\^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m\^2. Maintenance year one 1.0mg/m\^2 1,4,8,11 q 28 days.
Study NCT00081939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
Study NCT00422669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Dual-Chamber Pacemaker
Description: A Medtronic market-approved dual-chamber implantable pulse generator (IPG)
Study NCT00422669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic SelectSecure 3830 Lead
Description: Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
Study NCT00964600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP blockade
Description: 15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
Study NCT02156752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Treatment is based on Acceptance and Commitment Therapy
Study NCT02156752 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SR
Description: Treatment is based on Self-Regulation theory.
Study NCT02156752 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WLO
Description: Treatment is based on cooking tips and demonstrations.
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Youth Psychopathic Traits Inventory (YPI) (for children)
Description: self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.
Study NCT04324099 — intervention group
Intervention type: OTHER
Intervention: Reactive Proactive Questionnaire (RPQ) (for children)
Description: The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.
Study NCT02818764 — intervention group
Intervention type: DEVICE
Intervention: Electroencephalogram
Description: Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
Study NCT02818764 — intervention group
Intervention type: DEVICE
Intervention: Cerebral blood flow and oxygen extraction fraction
Description: NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
Study NCT02290496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Insomnia (CBT-I)
Description: Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
Study NCT02290496 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Hygiene (SH)
Description: Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
Study NCT01599065 — intervention group
Intervention type: OTHER
Intervention: Magnet or Off-On
Description: Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
Study NCT00934830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: 1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
Study NCT01754701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immediate iron
Description: Children who start 4 weeks of iron therapy on Day 0
Study NCT01754701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Delayed iron
Description: Children who start 4 weeks of iron therapy on Day 28
Study NCT02478632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subjects do not receive study medication in this study 202094
Description: Participants do not receive study medication in this study 202094.
Study NCT03065218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc sestamibi
Description: The administration of the diagnostic radioisotope, 99mTc sestambi, to image possible metastases in patients with differentiated thyroid cancer.
Study NCT04190719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal prehabilitation
Description: Paprika prehabilitation program content: patients will have choices for each activity. Messages and motivation will be reinforced by using a mobile app or leaflet advices, according to patient's preferences.~* Physical activity promotion by discovering ebike, personalised gymnastics and encouragement to increase the number of daily steps of patients, measured by a wristband and a mobile App~* An individualized nutritional optimization plan with dietary advices and protein supplementation (if necessary).~* Psychological support will be proposed through auto-hypnosis sensibilisation or management of stress with Cognitive Behavior Stress Management technics
Study NCT02889471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP with NB
Description: ERCP with NB catheter for introperative tans-nasobiliary cholangiography
Study NCT02889471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP alone
Description: ERCP alone followed with standard laparoscopic cholecystectomy
Study NCT02620644 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OCT Retinal GCC
Description: measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
Study NCT02171494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVAX Warfarin
Study NCT02171494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS Coumadin
Study NCT00810576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
Study NCT00810576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose of 1.3 mg/m\^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
Study NCT01771471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NuQu
Description: Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.
Study NCT01771471 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 0.9% w/v Sodium Chloride for Injection, USP
Study NCT02879357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: 1. Clinician training~2. System for patient selection~3. System of triggering and tracking conversations~4. Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values~5. Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR.
Study NCT00378404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
Study NCT00378404 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
Study NCT04086836 — intervention group
Intervention type: DEVICE
Intervention: TAVR
Description: Patient recieving a TAVR
Study NCT04041349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mouse nerve growth factor
Description: mouse nerve growth factor of 20 UG (9000 U)/day for 14 consecutive days by intramuscular injection
Study NCT02711683 — intervention group
Intervention type: DRUG
Intervention: DL-3-n-butylphthalide
Description: the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
Study NCT02711683 — intervention group
Intervention type: DRUG
Intervention: Donepezil
Description: the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
Study NCT02344719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taurin 6g per day per oral for 28 days
Description: Taurin 6g per day per oral for 28 days
Study NCT02344719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG Measurement baseline
Description: On day 1 (baseline) and day 28 HVPG measurement will be performed
Study NCT02344719 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HVPG Measurement baseline
Description: On day 1 (baseline) and day 28 HVPG measurement will be performed